NEW YORK (TheStreet) -- CHANGE IN RATINGS
Ann (ANN) was downgraded to neutral from buy at Janney Montgomery. $35 price target. Traffice is weakening, Janney said.
Cavium (CAVM) was upgraded to outperform from neutral at Wedbush. $42 price target. The company can deliver solid growht in 2014, Wedbush said.
[Read: Q4 Biotech Earnings Preview]
was downgraded to underweight from netural at J.P. Morgan. $17 price target. The company will be hurt by emerging market weakness, said J.P. Morgan.
E*Trade (ETFC) - Get E*TRADE Financial Corporation Report was upgraded to outperform from market perform by JMP Securities. $26 price target. Risks have diminished and the company is in the midst of a recovery, said JMP.
Mallinckrodt (MNK) - Get Mallinckrodt Plc Report was downgraded to sell from neutral at UBS. $43 price target. This is a valuation call as business has seen shrinking margins and supply disruptions, said UBS.
Merck (MRK) - Get Merck & Co., Inc. Report was upgraded to overweight from underweight by Morgan Stanley. $60 price target. The company is cutting costs and should see a positive oncology newsflow, said Morgan Stanley.
RetailMeNot (SALE) was upgraded to buy from neutral by Goldman Sachs. $40 price target. Mobile usage should improve traffic, Goldman said.
Stock Comments / EPS Changes
price target was raised at Pacific Crest. The company is positioned well for a strong 2014, said Pacific Crest. New price target of $475 and outperform rating.
DigitalGlobe (DGI) price target was raised at Jefferies. The change was driven by a rebalanced portfolio and high EBITDA margins and attractive FCF, said Jefferies. Buy rating and $50 price target.
[Read: Obama Urged to Act on Student Loan Refinance]
Enersys (ENS) - Get EnerSys Report price target was raised at Jefferies. The changed target is due to truck data trending higher, successful implementation of price increase in Europe and stronger F2H expected with pricing, volume and costs. Buy rating and new price target of $78.
FirstEnergy FE price target and earnings per share were cut by UBS. There is growing risk around execution of a new regulated growth strategy. Estimates were cut through 2015, according to UBS. $31 price target and neutral rating.
This article was written by a staff member of TheStreet.